CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)
(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

BIVALENT COVID-19 mRNA VACCINE (SYS6006.32) INCLUDED FOR EMERGENCY USE IN CHINA

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that, as proposed by the National Health Commission of the People's Republic of China and consented by the National Medical Products Administration (the "**NMPA**") after assessment, the bivalent COVID-19 mRNA vaccine (XBB.1.5+BQ.1) (SYS6006.32) developed by the Group (the "**Product**") has been included for emergency use in China for the prevention of COVID-19 caused by the infection of SARS-CoV-2.

SYS6006.32, targeting the dominant variants represented by XBB.1.5, is a bivalent mRNA vaccine against XBB.1.5 and BQ.1 variants developed by the Group on the foundation of the first generation COVID-19 mRNA vaccine (brand name: Duentai (度恩泰)), which has also been included for emergency use in China.

In the clinical trials, the Product not only induced very high immunogenicity against the dominant variants EG.5 and XBB.1.5, with live virus neutralizing antibody level 48 and 34 times the level before vaccination, and 4.9 and 5.0 times the level induced by Duentai respectively, but also induced broad-spectrum cross-variant immunity against variants including XBB.1.16, BA.5, XBB.2.3, and BA.2.86. This indicates that the Product may provide good protection against the current dominant strains as well as potential prevalent strains in the future. The Product also had a good safety profile. The types and severity of the most adverse reactions were comparable to Duentai, with no additional risks. The level of the neutralizing antibodies in the elderly group was comparable to the adult group, but with a better safety profile. This indicates that the Product may provide better protection for the elderly.

The Product adopts advanced technology with independent intellectual property rights, with the advantages of achieving higher production capacity, better process reproducibility, scale-up and large-scale production more easily. The Product demonstrates good consistency in product quality, all batches of samples submitted to the National Institutes for Food and Drug Control have passed the required tests. The Product is stable and can be stored at 2-8°C for a long time. Key raw materials and excipients used in the production, such as core lipids and cap analogs for mRNA preparation, are all manufactured by the Group, while other excipients and key equipment are all domestically sourced, thus no reliance on overseas suppliers in the supply chain.

The Product is another mRNA vaccine product that has been authorized for emergency use following Duentai, which demonstrates the research and development strength of the Group's nucleic acid platform. The Group will actively promote the development of other products on the platform.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 1 December 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.